Claims for Patent: 8,153,632

Summary for Patent: 8,153,632

Title:	Oxygen linked pyrimidine derivatives
Abstract:	The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to oxygen linked and substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumors and cancers as well as other disorders or conditions related to or associated with kinases.
Inventor(s):	Blanchard; Stephanie (Singapore, SG), Lee; Cheng Hsia Angeline (Singapore, SG), Nagaraj; Harish Kumar Mysore (Singapore, SG), Poulsen; Anders (Singapore, SG), Sun; Eric T. (Singapore, SG), Tan; Yee Ling Evelyn (Singapore, SG), William; Anthony Deodaunia (Singapore, SG)
Assignee:	S*BIO Pte Ltd. (Singapore, SG)
Application Number:	12/093,867
Patent Claims:	1. A compound of formula I: ##STR00155## wherein: R.sup.1 and R.sup.2 are each independently selected from the group consisting of: H, halogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, arylalkyloxy, phenoxy, benzyloxy, heteroaryloxy, amino, alkylamino, aminoalkyl, acylamino, arylamino, sulfonylamino, sulfinylamino, --COOH, --COR.sup.3, --COOR.sup.3, --CONHR.sup.3, --NHCOR.sup.3, --NHCOOR.sup.3, --NHCONHR.sup.3, alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, aminosulfonyl, --SR.sup.3, R.sup.4S(O)R.sup.6--, R.sup.4S(O).sub.2R.sup.6--, R.sup.4C(O)N(R.sup.5)R.sup.6--, R.sup.4SO.sub.2N(R.sup.5)R.sup.6--, R.sup.4N(R.sup.5)C(O)R.sup.6--, R.sup.4N(R.sup.5)SO.sub.2R.sup.6--, R.sup.4N(R.sup.5)C(O)N(R.sup.5)R.sup.6-- and acyl, each of which may be optionally substituted; each R.sup.3, R.sup.4, and R.sup.5 is independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl and acyl, each of which may be optionally substituted; each R.sup.6 is independently selected from the group consisting of a bond, alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl and acyl, each of which may be optionally substituted; Z.sup.2 is --N(R.sup.7)--; each R.sup.7 is independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl and acyl, each of which may be optionally substituted; Ar.sup.1 and Ar.sup.2 are both phenylene, each of which may be optionally substituted; L is a group of formula: --X.sup.1--Y--X.sup.2-- wherein X.sup.1 is attached to Ar.sup.1 and X.sup.2 is attached to Ar.sup.2, and wherein X.sup.1, X.sup.2 and Y are selected such that the group L has between 5 and 15 atoms in the normal chain, X.sup.1 and X.sup.2 are each independently a heteroalkyl group containing at least one oxygen atom in the normal chain, Y is a group of formula --CR.sup.a.dbd.CR.sup.b--, wherein R.sup.a and R.sup.b are each independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl and acyl, each of which may be optionally substituted, or R.sup.a and R.sup.b may be joined such that when taken together with the carbon atoms to which they are attached they form a cycloalkenyl or cycloheteroalkenyl group; or a pharmaceutically acceptable salt or N-oxide thereof. 2. A compound according to claim 1 wherein Z.sup.2 is --N(H)--. 3. A compound according to claim 1 wherein Ar.sup.1 is selected from the group consisting of: ##STR00156## wherein V.sup.1, V.sup.2, V.sup.3 and V.sup.4 are each independently C(R.sup.10); wherein each R.sup.10 is independently selected from the group consisting of: H, halogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, arylalkyloxy, phenoxy, benzyloxy, heteroaryloxy, amino, alkylamino, aminoalkyl, acylamino, arylamino, sulfonylamino, sulfinylamino, --COOH, --COR.sup.3, --COOR.sup.3, --CONHR.sup.3, --NHCOR.sup.3, --NHCOOR.sup.3, --NHCONHR.sup.3, alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, aminosulfonyl, --SR.sup.3, R.sup.4S(O)R.sup.6--, R.sup.4S(O).sub.2R.sup.6--, R.sup.4C(O)N(R.sup.5)R.sup.6--, R.sup.4SO.sub.2N(R.sup.5)R.sup.6--, R.sup.4N(R.sup.5)C(O)R.sup.6--, R.sup.4N(R.sup.5)SO.sub.2R.sup.6--, R.sup.4N(R.sup.5)C(O)N(R.sup.5)R.sup.6-- and acyl, each of which may be optionally substituted. 4. A compound according to claim 1 wherein Ar.sup.1 is: ##STR00157## wherein R.sup.10 is independently selected from the group consisting of: H, halogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, arylalkyloxy, phenoxy, benzyloxy, heteroaryloxy, amino, alkylamino, aminoalkyl, acylamino, arylamino, sulfonylamino, sulfinylamino, --COOH, --COR.sup.3, --COOR.sup.3, --CONHR.sup.3, --NHCOR.sup.3, --NHCOOR.sup.3, --NHCONHR.sup.3, alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, aminosulfonyl, --SR.sup.3, R.sup.4S(O)R.sup.6--, R.sup.4S(O).sub.2R.sup.6--, R.sup.4C(O)N(R.sup.5)R.sup.6--, R.sup.4SO.sub.2N(R.sup.5)R.sup.6--, R.sup.4N(R.sup.5)C(O)R.sup.6--, R.sup.4N(R.sup.5)SO.sub.2R.sup.6--, R.sup.4N(R.sup.5)C(O)N(R.sup.5)R.sup.6-- and acyl, each of which may be optionally substituted; and k is an integer selected from the group consisting of 0, 1, 2, 3, and 4. 5. A compound according to claim 1 wherein Ar.sup.2 is a group selected from the group consisting of: ##STR00158## wherein each R.sup.11 is independently selected from the group consisting of: H, halogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, arylalkyloxy, phenoxy, benzyloxy, heteroaryloxy, amino, alkylamino, aminoalkyl, acylamino, arylamino, sulfonylamino, sulfinylamino, --COOH, --COR.sup.3, --COOR.sup.3, --CONHR.sup.3, --NHCOR.sup.3, --NHCOOR.sup.3, --NHCONHR.sup.3, alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, aminosulfonyl, --SR.sup.3, R.sup.4S(O)R.sup.6--, R.sup.4S(O).sub.2R.sup.6--, R.sup.4C(O)N(R.sup.5)R.sup.6--, R.sup.4SO.sub.2N(R.sup.5)R.sup.6--, R.sup.4N(R.sup.5)C(O)R.sup.6--, R.sup.4N(R.sup.5)SO.sub.2R.sup.6--, R.sup.4N(R.sup.5)C(O)N(R.sup.5)R.sup.6-- and acyl, each of which may be optionally substituted. 6. A compound according to claim 1 wherein the compound is: ##STR00159## wherein R.sup.10 and R.sup.11 are independently selected from the group consisting of: H, halogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, arylalkyloxy, phenoxy, benzyloxy, heteroaryloxy, amino, alkylamino, aminoalkyl, acylamino, arylamino, sulfonylamino, sulfinylamino, --COOH, --COR.sup.3, --COOR.sup.3, --CONHR.sup.3, --NHCOR.sup.3, --NHCOOR.sup.3, --NHCONHR.sup.3, alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, aminosulfonyl, --SR.sup.3, R.sup.4S(O)R.sup.6--, R.sup.4S(O).sub.2R.sup.6--, R.sup.4C(O)N(R.sup.5)R.sup.6--, R.sup.4SO.sub.2N(R.sup.5)R.sup.6--, R.sup.4N(R.sup.5)C(O)R.sup.6--, R.sup.4N(R.sup.5)SO.sub.2R.sup.6--, R.sup.4N(R.sup.5)C(O)N(R.sup.5)R.sup.6-- and acyl, each of which may be optionally substituted; k is an integer selected from the group consisting of 0, 1, 2, 3, and 4; and o is an integer selected from the group consisting of 0, 1, 2, 3 and 4; or a pharmaceutically acceptable salt thereof. 7. A compound according to claim 1 wherein X.sup.1 and X.sup.2 are each independently selected from the group consisting of: (a) --OC.sub.1-5alkyl-, (b) --C.sub.1-5alkylO-, and (c) --C.sub.1-5alkylOC.sub.1-5alkyl. 8. A compound according to claim 1 wherein X.sup.1 is selected from the group consisting of: (a) --OCH.sub.2-- (b) --CH.sub.2O--, (c) --OCH.sub.2CH.sub.2--, (d) --CH.sub.2CH.sub.2O--, (e) --CH.sub.2OCH.sub.2--, and (f) --CH.sub.2CH.sub.2OCH.sub.2--. 9. A compound according to claim 1 wherein X.sup.2 is selected from the group consisting of: (a) --OCH.sub.2-- (b) --CH.sub.2O--, (c) --OCH.sub.2CH.sub.2--, (d) --CH.sub.2CH.sub.2O--, (e) --CH.sub.2OCH.sub.2--, and (f) --CH.sub.2CH.sub.2OCH.sub.2--. 10. A compound according to claim 1 selected from the group consisting of: ##STR00160## wherein R.sup.10 and R.sup.11 are independently selected from the group consisting of: H, halogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, arylalkyloxy, phenoxy, benzyloxy, heteroaryloxy, amino, alkylamino, aminoalkyl, acylamino, arylamino, sulfonylamino, sulfinylamino, --COOH, --COR.sup.3, --COOR.sup.3, --CONHR.sup.3, --NHCOR.sup.3, --NHCOOR.sup.3, --NHCONHR.sup.3, alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, aminosulfonyl, --SR.sup.3, R.sup.4S(O)R.sup.6--, R.sup.4S(O).sub.2R.sup.6--, R.sup.4C(O)N(R.sup.5)R.sup.6--, R.sup.4SO.sub.2N(R.sup.5)R.sup.6--, R.sup.4N(R.sup.5)C(O)R.sup.6--, R.sup.4N(R.sup.5)SO.sub.2R.sup.6--, R.sup.4N(R.sup.5)C(O)N(R.sup.5)R.sup.6-- and acyl, each of which may be optionally substituted; k is an integer selected from the group consisting of 0, 1, 2, 3, and 4; and o is an integer selected from the group consisting of 0, 1, 2, 3 and 4; or a pharmaceutically acceptable salt thereof. 11. A compound according to claim 1 wherein R.sup.1 and R.sup.2 are independently selected from the group consisting of H and methyl. 12. A compound according to claim 4 wherein each R.sup.10 is independently selected from the group consisting of H, halogen, amino, alkyl, haloalkyl, haloalkenyl, heterocycloalkyl, aryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, and alkoxyalkyl, each of which may be optionally substituted. 13. A compound according to claim 4 wherein each R.sup.10 is independently selected from the group consisting of H, hydroxyl, methoxy, fluoro, methyl, ethyl, propyl, butyl, pentyl, hexyl, phenyl, and 2-morpholino-ethoxy, each of which may be optionally substituted. 14. A compound according to claim 12 wherein each R.sup.11 is independently selected from the group consisting of H, alkoxy, heteroalkyl, heterocycloalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, and arylsulfonyloxy, each of which may be optionally substituted. 15. A compound according to claim 12 wherein each R.sup.11 is independently selected from the group consisting of: ##STR00161## 16. A compound according to claim 1 wherein Y is selected from the group consisting of: ##STR00162## 17. A compound according to claim 1 wherein the optional substituent is selected from the group consisting of: halogen, .dbd.O, .dbd.S, --CN, --NO.sub.2, --CF.sub.3, --OCF.sub.3, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkoxyheteroaryl, alkenyloxy, alkynyloxy, cycloalkyloxy, cycloalkenyloxy, heterocycloalkyloxy, heterocycloalkenyloxy, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, arylalkyloxy, -amino, alkylamino, acylamino, aminoalkyl, arylamino, sulfonyl, alkylsulfonyl, arylsulfonyl, aminosulfonyl, aminoalkyl, alkoxyalky, --COOH, --COR.sup.5, --C(O)OR.sup.5, --SH, --SR.sup.5, --OR.sup.6 and acyl. 18. A compound according to claim 1 selected from the group consisting of: ##STR00163## ##STR00164## ##STR00165## ##STR00166## ##STR00167## ##STR00168## ##STR00169## ##STR00170## ##STR00171## or a pharmaceutically acceptable salt thereof. 19. A pharmaceutical composition including a compound according to claim 1 and a pharmaceutically acceptable diluent, excipient or carrier. 20. A method of inhibiting one or more protein kinase(s) including exposing the one or more protein kinase(s) and/or co-factor(s) thereof to an effective amount of a compound according to claim 1. 21. A method according to claim 20 wherein the one or more protein kinase(s) is a cyclin-dependent protein kinase or a protein tyrosine kinase. 22. A method according to claim 21 wherein the cyclin-dependent kinase is a Group I CMCG kinase selected from the group consisting of CDC2Hs, CDK2, CDK3, CDK4, CDK5, CDK6, CDK9, PCTAIRE1, PCTAIRE2, PCTAIRE3, CAK/MO15, Dm2, Dm2c, Ddcdc2, DdPRK, LmmCRK1, PfC2R, EhC2R, CfCdc2R, cdc2+, CDC28, PHO85, KIN28, FpCdc2, MsCdc2B, and OsC2R or a functional equivalent thereof. 23. A method according to claim 22 wherein the Group I CMCG kinase is CDK2 or a functional equivalent thereof. 24. A method according to claim 21 wherein the protein tyrosine kinase is a Group VII protein tyrosine kinase or a Group XIV protein tyrosine kinase. 25. A method according to claim 24 wherein the Group VII protein tyrosine kinase is selected from the group consisting of TYK2, JAK1, JAK2 and HOP or a functional equivalent thereof. 26. A method according to claim 25 wherein the Group VII protein tyrosine kinase is JAK2 or a functional equivalent thereof. 27. A method according to claim 26 wherein the JAK2 includes a V to F mutation at position 617. 28. A method according to claim 24 wherein the Group XIV protein tyrosine kinase is selected from the group consisting of PDGFR-.beta., PDGFR-.alpha., CSF1R, c-kit, Flk2, FLT1, FLT2, FLT3 and FLT4 or a functional equivalent thereof. 29. A method according to claim 28 wherein the Group XIV protein tyrosine kinase is FLT3 or a functional equivalent thereof. 30. A method according to claim 29 wherein the FLT3 includes an internal tandem duplication of amino acids VDFREYEYDH at position 592-601. 31. A method of synthesis of a compound of formula I as defined in claim 1 the method including the steps of: (a) providing a compound of the formula ##STR00172## (b) subjecting the compound to ring closing metathesis; (c) optionally reacting the double bond thus formed to form a cycloalkyl group. 32. A method according to claim 31 wherein step (b) involves treating the trifluoroacetic acid (TFA) or hydrochloric acid (HCl) salt of the compound with 5-10 mole % of Grubbs 2.sup.nd generation catalyst in dichloromethane at 40.degree. C. 33. A method according to claim 31 wherein step (c) includes treating the metathesis product with a freshly prepared ethereal solution of diazomethane (CH.sub.2N.sub.2) in dichloromethane/dioxane at 0.degree. C.